The KRT18 Knockout Ca Ski Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Ca Ski cervical carcinoma line, engineered to disrupt the KRT18 gene. This product provides a loss-of-function model in which the targeted gene disruption abrogates keratin 18 protein expression within a heterogeneous pool of edited cells, avoiding clonal artifacts and maintaining population-level diversity. The knockout is generated using CRISPR/Cas9-mediated gene disruption, yielding a versatile system for investigating structural and signaling roles of keratin 18 in epithelial cancer biology. The polyclonal format preserves the cellular heterogeneity inherent to tumor cell populations, making it suitable for studies requiring a representative knockout background without single-cell clone selection.
The host cell line, Ca Ski, originates from a human cervical squamous cell carcinoma and serves as an established model for cervical cancer research. These adherent epithelial cells retain key characteristics of the primary tumor, including dysregulated proliferation and aberrant differentiation. Ca Ski cells are widely employed to dissect oncogenic signaling, test therapeutic compounds, and examine tumor cell behavior in vitro. Their cervical carcinoma origin positions them uniquely for mechanistic studies on intermediate filament dynamics in the context of squamous cell carcinomas, where keratin networks are essential for maintaining tissue architecture and withstanding mechanical stress.
Keratin 18 (KRT18) encodes a type I intermediate filament protein that obligately heterodimerizes with its type II partner keratin 8 (KRT8) to form the intermediate filament cytoskeleton in simple and glandular epithelia. Beyond its structural role, KRT18 serves as a principal caspase substrate during apoptosis; it is cleaved by caspases-3, -6, and -7 downstream of death receptor activation by TNF-alpha or Fas ligand, events regulated upstream by TP53. Cleavage generates fragments that promote filament disassembly and expose binding sites for 14-3-3 proteins, which sequester key pro-apoptotic factors and modulate caspase activation. The KRT8/KRT18 network interacts with desmoplakin at desmosomes and with adaptor proteins such as TRADD in the TNFR1 signaling complex, linking mechanical integrity to cell death pathways. Knockout of KRT18 therefore depletes this obligate heterodimer, destabilizing the entire keratin network and perturbing both cytoskeletal organization and apoptotic signaling.
In the Ca Ski cervical carcinoma background, KRT18 knockout carries significant implications for tumor cell biology. Loss of the KRT8/KRT18 network impairs epithelial mechanical integrity, likely reducing cell stiffness and altering migratory and invasive potential ?C phenotypes directly relevant to cervical cancer progression. Furthermore, disruption of KRT18-mediated caspase processing may dysregulate apoptotic responses, potentially influencing sensitivity to chemotherapeutic agents or death receptor agonists. This model enables dissection of keratin-dependent versus -independent aspects of epithelial-derived tumor cell behavior, offering a platform to study how intermediate filament loss reshapes signaling networks and physical properties in a disease-relevant context. It also provides a tool to investigate the role of KRT18 accumulation in Mallory-Denk bodies, although the Ca Ski line is primarily a cervical model.
The KRT18 Knockout Ca Ski Polyclonal Cells are well-suited for a wide range of experimental applications. Researchers can perform western blotting and immunofluorescence to confirm keratin network ablation, measure cell stiffness using atomic force microscopy or microindentation, and assess migration and invasion in transwell assays. Apoptosis studies benefit from flow cytometric detection of caspase-cleaved keratin 18 fragments or annexin V staining, alongside caspase activity assays. The knockout model supports drug testing in cervical carcinoma, where altered mechanical or apoptotic responses may reveal therapeutic vulnerabilities. Gene expression and protein interaction analyses can map changes in the TNFR1/TRADD/caspase-8 and Fas/FADD/caspase-8 axes. For additional technical information, please contact Ascent Research.
